Rideout W M, Coetzee G A, Olumi A F, Jones P A
Urological Cancer Research Laboratory, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles 90033.
Science. 1990 Sep 14;249(4974):1288-90. doi: 10.1126/science.1697983.
Direct genomic sequencing revealed that cytosine residues known to have undergone a germ-line mutation in the low density lipoprotein receptor gene or somatic mutations in the p53 tumor suppressor gene were methylated in all normal human tissues analyzed. Thus, these mutations should be scored as transitions from 5-methylcytosine to thymine rather than from cytosine to thymine. Methylated cytosines occur exclusively at CpG dinucleotides, which, although markedly underrepresented in human DNA, are sites for more than 30 percent of all known disease-related point mutations. Thus, 5-methylcytosine functions as an endogenous mutagen and carcinogen in humans, in that methylation seems to increase the potential for mutation at cytosine residues at least by a factor of 10.
直接基因组测序显示,在低密度脂蛋白受体基因中已知发生种系突变或p53肿瘤抑制基因中发生体细胞突变的胞嘧啶残基,在所有分析的正常人体组织中均被甲基化。因此,这些突变应被记为从5-甲基胞嘧啶到胸腺嘧啶的转变,而不是从胞嘧啶到胸腺嘧啶的转变。甲基化的胞嘧啶仅出现在CpG二核苷酸处,尽管其在人类DNA中明显含量不足,但却是所有已知疾病相关点突变的30%以上的位点。因此,5-甲基胞嘧啶在人类中作为一种内源性诱变剂和致癌物起作用,因为甲基化似乎至少将胞嘧啶残基处的突变可能性提高了10倍。